These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 15774575)

  • 1. Complement factor H as a marker for detection of bladder cancer.
    Cheng ZZ; Corey MJ; Pärepalo M; Majno S; Hellwage J; Zipfel PF; Kinders RJ; Raitanen M; Meri S; Jokiranta TS
    Clin Chem; 2005 May; 51(5):856-63. PubMed ID: 15774575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins.
    Antonioli AH; White J; Crawford F; Renner B; Marchbank KJ; Hannan JP; Thurman JM; Marrack P; Holers VM
    J Immunol; 2018 Jan; 200(1):316-326. PubMed ID: 29187587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells.
    Leffler J; Herbert AP; Norström E; Schmidt CQ; Barlow PN; Blom AM; Martin M
    J Biol Chem; 2010 Feb; 285(6):3766-3776. PubMed ID: 19951950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor H-related protein 1 promotes complement-mediated opsonization of
    González-Alsina A; Martín-Merinero H; Mateu-Borrás M; Verd M; Doménech-Sánchez A; Goldberg JB; Rodríguez de Córdoba S; Albertí S
    Front Cell Infect Microbiol; 2024; 14():1328185. PubMed ID: 38510967
    [No Abstract]   [Full Text] [Related]  

  • 5. Purification, quantification, and functional analysis of Complement Factor H.
    Yu BB; Moffatt BE; Fedorova M; Villiers CG; Arnold JN; Du E; Swinkels A; Li MC; Ryan A; Sim RB
    Methods Mol Biol; 2014; 1100():207-23. PubMed ID: 24218262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement Factor H-Related Protein 4A Is the Dominant Circulating Splice Variant of
    Pouw RB; Brouwer MC; van Beek AE; Józsi M; Wouters D; Kuijpers TW
    Front Immunol; 2018; 9():729. PubMed ID: 29719534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder.
    Kinders R; Jones T; Root R; Bruce C; Murchison H; Corey M; Williams L; Enfield D; Hass GM
    Clin Cancer Res; 1998 Oct; 4(10):2511-20. PubMed ID: 9796985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.
    Chaffer CL; Brennan JP; Slavin JL; Blick T; Thompson EW; Williams ED
    Cancer Res; 2006 Dec; 66(23):11271-8. PubMed ID: 17145872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human factor H protein family - an update.
    Sándor N; Schneider AE; Matola AT; Barbai VH; Bencze D; Hammad HH; Papp A; Kövesdi D; Uzonyi B; Józsi M
    Front Immunol; 2024; 15():1135490. PubMed ID: 38410512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.
    Naryzhny S; Ronzhina N; Zorina E; Kabachenko F; Klopov N; Zgoda V
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Circulating Serum Protein Biomarkers of Non-Muscle Invasive Bladder Cancer after Protein Corona-Silver Nanoparticles Analysis by SWATH-MS.
    Gómez BB; López-Cortés R; Casas-Nebra FJ; Vázquez-Estévez S; Pérez-Fentes D; Chantada-Vázquez MDP; Bravo SB; Núñez C
    Nanomaterials (Basel); 2021 Sep; 11(9):. PubMed ID: 34578700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement System: Promoter or Suppressor of Cancer Progression?
    Revel M; Daugan MV; Sautés-Fridman C; Fridman WH; Roumenina LT
    Antibodies (Basel); 2020 Oct; 9(4):. PubMed ID: 33113844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine biopsy technologies: Cancer and beyond.
    Chen CK; Liao J; Li MS; Khoo BL
    Theranostics; 2020; 10(17):7872-7888. PubMed ID: 32685026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles.
    Oliveira MC; Caires HR; Oliveira MJ; Fraga A; Vasconcelos MH; Ribeiro R
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32485907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the Complement System by Pentraxins.
    Haapasalo K; Meri S
    Front Immunol; 2019; 10():1750. PubMed ID: 31428091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement in Metastasis: A Comp in the Camp.
    Ajona D; Ortiz-Espinosa S; Pio R; Lecanda F
    Front Immunol; 2019; 10():669. PubMed ID: 31001273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative recurrence of epithelial ovarian cancer patients and chemoresistance related protein analyses.
    Zhang Z; Qin K; Zhang W; Yang B; Zhao C; Zhang X; Zhang F; Zhao L; Shan B
    J Ovarian Res; 2019 Mar; 12(1):29. PubMed ID: 30917846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic biomarkers in non-muscle invasive bladder cancer.
    Faiena I; Rosser CJ; Chamie K; Furuya H
    World J Urol; 2019 Oct; 37(10):2009-2016. PubMed ID: 30467596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contemporary role and impact of urine-based biomarkers in bladder cancer.
    Duquesne I; Weisbach L; Aziz A; Kluth LA; Xylinas E;
    Transl Androl Urol; 2017 Dec; 6(6):1031-1042. PubMed ID: 29354490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling in bladder cancer identifies potential therapeutic targets.
    Hussain SA; Palmer DH; Syn WK; Sacco JJ; Greensmith RMD; Elmetwali T; Aachi V; Lloyd BH; Jithesh PV; Arrand J; Barton D; Ansari J; Sibson DR; James ND
    Int J Oncol; 2017 Apr; 50(4):1147-1159. PubMed ID: 28259975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.